Companies Dominating the Anabolic Steroids Landscape
- Mylan N.V.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Johnson & Johnson Private Limited
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd.
- Merck & Co., Inc.
Browse Key Market Insights with Data Illustration:
In the News
- April 2019: Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced the introduction of AndroGel ®i 1.62% CIII as a generic drug in the United States. For the treatment of disorders related to a lack of endogenous testosterone in adult males, such as primary hypogonadism and hypogonadotropic hypogonadism, testosterone Gel 1.62% CIII is recommended. Teva is the market leader in first-to-file opportunities, with over 100 pending first-to-files in the United States, and has the largest portfolio of FDA-approved generic drugs, with approximately 500 generic medications available. Teva generic products are currently used to fill one in every eight generic prescriptions that are written in the United States.
- December 2022: Pfizer Inc. reported that a New Drug Application (NDA) for etrasimod for people with moderately-to-severely active ulcerative colitis (UC) has been accepted for consideration by the U.S. Food and Drug Administration (FDA). The FDA's choice is anticipated in 2023's second half. The Marketing Authorization Application (MAA) for etrasimod in the same patient population has also been accepted by the European Medicines Agency (EMA), and a decision is expected in the first half of 2024.
